Breast Cancer Research and Treatment

, Volume 128, Issue 1, pp 211–218 | Cite as

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants

  • L. Delgado
  • G. Fernández
  • G. Grotiuz
  • S. Cataldi
  • A. González
  • N. LLuveras
  • M. Heguaburu
  • R. Fresco
  • D. Lens
  • G. Sabini
  • I. M. Muse
Epidemiology

Abstract

The aim of the present study was to analyze BRCA1 and BRCA2 mutations in Uruguayan families with breast and breast/ovarian cancer. Probands from 42 families with at least three cases of female breast cancer (BC) or two cases and subcriteria (paternal transmission, ovarian cancer, bilateral BC, male BC, Ashkenazi Jewish ancestry) in the same lineage, at least one diagnosed before age 50, were screened for germline mutations. PCR amplification of all exons and intron–exon boundaries were performed, followed by protein truncation test, heteroduplex analysis, and direct sequencing. We identified seven different truncating mutations in seven families, five in BRCA2 (three in site-specific BC families and two in breast–ovarian cancer families) and two in BRCA1 (one in a site-specific BC family and the other in a breast–ovarian cancer family). Both BRCA1 mutations (5583insT and 2687T>G) and one of the five BRCA2 mutations (3829insTdel35) were not previously reported. We also detected ten sequence variants of unknown significance, five of them not described before. The low frequency of BRCA1/2 mutations (0.17) is in agreement with that reported in studies which included families with similar selection criteria. However, the observed predominance of BRCA2 (0.12) over BRCA1 mutations (0.05) is in contrast with the higher proportion of BRCA1 mutations communicated for most previous studies, even those with a predominance of site-specific BC families. Meanwhile, it has been described in one Chilean and some Spanish and Italian reports, highlighting the strong dependence between the mutational spectra and the ethnicity of the population analyzed.

Keywords

BRCA1 BRCA2 Breast cancer Germ-line mutations Uruguay 

References

  1. 1.
    Vasallo JA, De Stefani E, Barrios E, Ronco A (2001) II Atlas de incidencia del cáncer en Uruguay 1996–1997. CHLCC, MontevideoGoogle Scholar
  2. 2.
    Vasallo JA, Barrios E (1999) III Atlas de mortalidad por cáncer en el Uruguay. Comparación de 2 quinquenios 1994–1998 y 1999–2003. CHLCC, MontevideoGoogle Scholar
  3. 3.
    Arver B, Quan Du, Chen J, Luo L, Lindblon A (2000) Hereditary breast cancer: a review. Cancer Biol 10:271–288CrossRefGoogle Scholar
  4. 4.
    Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 85:16–28CrossRefGoogle Scholar
  5. 5.
    Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Sholnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRefGoogle Scholar
  6. 6.
    Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Keisell D, Ford D, Tonin P, Biship DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRefGoogle Scholar
  7. 7.
    Breast Cancer Information Core database: http://researc.nhgri.nih.gov/bic/. Accessed 4 Aug 2010
  8. 8.
    Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRefGoogle Scholar
  9. 9.
    Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi 93–vi 98Google Scholar
  10. 10.
    Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020PubMedGoogle Scholar
  11. 11.
    Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86(11 Suppl):2575–2582PubMedCrossRefGoogle Scholar
  12. 12.
    Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391PubMedCrossRefGoogle Scholar
  13. 13.
    Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMedGoogle Scholar
  14. 14.
    Sans M, Salzano FM, Chakraborty R (1997) Historical genetics in Uruguay: estimates of biological origins and their problems. Hum Biol 69(2):161–170PubMedGoogle Scholar
  15. 15.
    Gascue C, Mimbacas A, Sans M, Gallino JP, Bertoni B, Hidalgo P, Cardoso H (2005) Frequencies of the four major Amerindian mtDNA haplogroups in the population of Montevideo, Uruguay. Hum Biol 77(6):873–878PubMedCrossRefGoogle Scholar
  16. 16.
    Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderón-Garcidueñas AL, Chopin S, Fabrice JF, González-Guerrero JF, Szabo C, Lenoir G, Goldgar D, Barrera-Saldaña H (2002) BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat 20:474–475PubMedCrossRefGoogle Scholar
  17. 17.
    Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166(1):36–45PubMedCrossRefGoogle Scholar
  18. 18.
    Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau R, King MC, Camus M, Alvarez M, Carvallo P (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95:81–87PubMedCrossRefGoogle Scholar
  19. 19.
    Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103(3):349–353PubMedCrossRefGoogle Scholar
  20. 20.
    Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 30(5):527–530PubMedGoogle Scholar
  21. 21.
    Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60:1031–1040PubMedGoogle Scholar
  22. 22.
    Mullineax LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL (2003) Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 98:597–602CrossRefGoogle Scholar
  23. 23.
    Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B (2007) BRCA1 and BRCA2 genetic testing in hispanic patients: mutation prevalence and evaluation of the BRCAPRO. Risk Assess Model J Clin Oncol 25:4635–4641Google Scholar
  24. 24.
    Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1998) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362Google Scholar
  25. 25.
    Delgado L, Fernández G, González A, Bressac-de Paillerets B, Gualco G, Bombled J, Cataldi S, Sabini G, Roca R, Musé IM (2002) Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genet Cytogenet 133(1):24–28PubMedCrossRefGoogle Scholar
  26. 26.
    Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JG, Vasen HF, Meijers-Heijboer H, Menko F, Cornelisse C, Dunnen J, Devilee P, Ommen G-J (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10(2):208–212PubMedCrossRefGoogle Scholar
  27. 27.
    Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60(3):486–495PubMedGoogle Scholar
  28. 28.
    Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H (2001) Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 37(16):2082–2090PubMedCrossRefGoogle Scholar
  29. 29.
    Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T (1997) Transcriptional activation functions in BRCA2. Nature 386:772–773PubMedCrossRefGoogle Scholar
  30. 30.
    Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germlinemutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742PubMedCrossRefGoogle Scholar
  31. 31.
    Liede A, Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96(1):11–15CrossRefGoogle Scholar
  32. 32.
    Díez O, Cortés J, Domènech M, Brunet J, Del Río E, Pericay C, Sanz J, Alonso C, Baiget M (1999) BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families. Int J Cancer 83(4):465–469PubMedCrossRefGoogle Scholar
  33. 33.
    De la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97(4):466–471CrossRefGoogle Scholar
  34. 34.
    Ottini L, D’Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R (2000) BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2(4):307–310PubMedCrossRefGoogle Scholar
  35. 35.
    Turchetti D, Cortesi L, Federico M, Bertoni C, Mangone L, Ferrari S, Silingardi V (2000) BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. Eur J Cancer 36(16):2083–2089PubMedCrossRefGoogle Scholar
  36. 36.
    Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD, Pizzichetta MA, Tibiletti MG, Gallo A, Tumolo S, Del Tin L, Boiocchi M (1998) Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int J Cancer 78(5):581–586PubMedCrossRefGoogle Scholar
  37. 37.
    Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A (1999) BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 83(1):5–9PubMedCrossRefGoogle Scholar
  38. 38.
    Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82(7):1266–1270PubMedCrossRefGoogle Scholar
  39. 39.
    Díez O, Osorio A, Durán M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodríguez-López R, Velasco E, Chaves J, Díaz-Rubio E, Jesús Cruz J, Torres M, Esteban E, Cervantes A, Alonso C, San Román JM, González-Sarmiento R, Miner C, Carracedo A, Eugenia Armengod M, Caldés T, Benítez J, Baiget M (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian câncer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22(4):301–312PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • L. Delgado
    • 1
  • G. Fernández
    • 2
  • G. Grotiuz
    • 2
  • S. Cataldi
    • 1
  • A. González
    • 2
  • N. LLuveras
    • 2
  • M. Heguaburu
    • 2
  • R. Fresco
    • 1
  • D. Lens
    • 2
  • G. Sabini
    • 1
  • I. M. Muse
    • 3
  1. 1.Department of Clinical Oncology, Clinical HospitalUniversity of UruguayMontevideoUruguay
  2. 2.University of UruguayMontevideoUruguay
  3. 3.National Cancer Control Program (Pronaccan)Ministry of Public HealthMontevideoUruguay

Personalised recommendations